ADVANCE infectious diseases pharmacy and LEAD antimicrobial stewardship in order
to OPTIMIZE the care of patients

Novel PrEP data from CROI 2014 published

17 Mar 2014 7:54 PM | Christopher McCoy

Data presented at CROI in Boston was recently published in Science detailing the use of a depot injection of a new integrase inhibitor that protected macaques from simian/human immunodeficiency virus infection for at least 6 weeks.  PrEP is currently limited to Truvada with ongoing studies of vaginal rings implanted with NNRTI's and topical agents including tenofovir gel. The Truvada prevention study results were notable for lesser protection with low medication adherence.  A depot approach would alleviate this potential.  The studies remain limited to animals.


Society of Infectious Diseases Pharmacists •  403 W. Saint Charles, Suite B, Lombard, IL 60148
(331) 248-7888sidp@affinity-strategies.com
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software